1. Home
  2. MBOT vs IPHA Comparison

MBOT vs IPHA Comparison

Compare MBOT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBOT
  • IPHA
  • Stock Information
  • Founded
  • MBOT 2010
  • IPHA 1999
  • Country
  • MBOT United States
  • IPHA France
  • Employees
  • MBOT N/A
  • IPHA N/A
  • Industry
  • MBOT Medical/Dental Instruments
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBOT Health Care
  • IPHA Health Care
  • Exchange
  • MBOT Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • MBOT 184.8M
  • IPHA 160.1M
  • IPO Year
  • MBOT N/A
  • IPHA 2019
  • Fundamental
  • Price
  • MBOT $3.42
  • IPHA $2.08
  • Analyst Decision
  • MBOT Strong Buy
  • IPHA Strong Buy
  • Analyst Count
  • MBOT 1
  • IPHA 1
  • Target Price
  • MBOT $12.00
  • IPHA $11.00
  • AVG Volume (30 Days)
  • MBOT 6.9M
  • IPHA 10.2K
  • Earning Date
  • MBOT 11-12-2025
  • IPHA 09-17-2025
  • Dividend Yield
  • MBOT N/A
  • IPHA N/A
  • EPS Growth
  • MBOT N/A
  • IPHA N/A
  • EPS
  • MBOT N/A
  • IPHA N/A
  • Revenue
  • MBOT N/A
  • IPHA $20,831,349.00
  • Revenue This Year
  • MBOT N/A
  • IPHA $350.96
  • Revenue Next Year
  • MBOT $728.02
  • IPHA $32.92
  • P/E Ratio
  • MBOT N/A
  • IPHA N/A
  • Revenue Growth
  • MBOT N/A
  • IPHA N/A
  • 52 Week Low
  • MBOT $0.85
  • IPHA $1.29
  • 52 Week High
  • MBOT $4.67
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • MBOT 48.25
  • IPHA 49.16
  • Support Level
  • MBOT $3.54
  • IPHA $1.93
  • Resistance Level
  • MBOT $4.25
  • IPHA $2.06
  • Average True Range (ATR)
  • MBOT 0.44
  • IPHA 0.10
  • MACD
  • MBOT -0.05
  • IPHA -0.01
  • Stochastic Oscillator
  • MBOT 13.79
  • IPHA 51.51

About MBOT Microbot Medical Inc.

Microbot Medical Inc is a clinical-stage medical device company specializing in the research, design and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is focused on leveraging its robotic technologies to redefine surgical robotics while improving surgical outcomes for patients. Using its LIBERTY technological platform, the company is developing the first-ever fully disposable robot for various endovascular interventional procedures.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: